Clinical Trial Update: A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update for MORAb-202 in previously treated metastatic non-small cell lung cancer with adenocarcinoma histology, which has been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• MORAb-202

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: TERMINATED | Results posted: 2025-09-04